Why did 4593.T stock jump pre-market?

4593.T stock rose on 23 Jan 2026 due to heavy volume and positioning ahead of an earnings announcement on 16 Feb 2026, plus sector rotation into biotech. Volume was **14,199,800.00**, well above the average **3,234,137.00**.

What is Meyka AI’s view on 4593.T stock?

Meyka AI rates 4593.T with a score of **65.93** (grade B, HOLD). The model highlights pipeline potential but flags negative EPS **-60.80** and stretched valuation. This is informational, not investment advice.

What price targets exist for 4593.T stock?

Meyka AI's model projects **JPY 467.21** (monthly) and **JPY 566.10** (quarterly). We outline a base case **JPY 340.00**, bullish **JPY 566.10**, and downside **JPY 220.00**. Forecasts are model projections, not guarantees.

What are the main risks for 4593.T stock?

Key risks are negative operating cash flow, clinical trial delays, and high valuation versus peers. Healios reports operating cash flow per share **-25.16** and high price-to-sales **436.68**, increasing sensitivity to news and funding.

JP Stocks

4593.T Healios K.K. (JPX) up 15.11% pre-market 23 Jan 2026: model projects 22–49% upside

ByDanny Kontos January 22, 2026January 22, 2026

Healios K.K. (4593.T) leads Japan pre-market gainers after a 15.11% jump to JPY 381.00 on heavy trading ahead of February results. The spike shows 14,199,800.00 shares changing hands versus an average of 3,234,137.00, a relative volume of 5.42. Short-term buying appears tied to positioning ahead of an earnings announcement on 16 Feb 2026 and sector rotation into healthcare biotech. This note examines drivers, valuation, technicals and Meyka AI’s model forecasts for 4593.T stock.